PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

Sponsor
Hansoh BioMedical R&D Company
Study ID
NCT07645222
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • HS-20122+Aumolertinib — DRUG
    EGFR mut NSCLC, receive HS-20122+Aumolertinib
  • HS-20122+Adbrelimab — DRUG
    EGFRwt NSCLC,receive HS-20122+Adbrelimab
  • HS-20122+Adbrelimab+Platinum-based Chemo — DRUG
    EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo

Study Details

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Key Dates

First listed
Jun 12, 2026
Start date
Jun 15, 2026
Status verified
Jul 2026
Primary completion
Oct 31, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
396 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HS-20122+Aumolertinib
  • Experimental: HS-20122+Adbrelimab
  • Experimental: HS-20122+Adbrelimab+Platinum-based Chemo

Primary Outcome Measure

RP2D for Combination [ Time Frame: Through the full duration of this trial, approximately 2 years ]

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies